Medexus Pharma Resubmits Treosulfan NDA To FDA
(RTTNews) - Medexus Pharmaceuticals (MDP.TO, MEDXF.OB) and its strategic partner medac announced Monday that medac has resubmitted its New Drug Application (NDA) for treosulfan with the U.S. Food and Drug Administration (FDA).
The current submission was a response to the FDA request to submit information to complete medac's April 2022 NDA resubmission and initiate FDA review.
The NDA requests approval of treosulfan in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
The current submission includes updates to data files and supporting information in response to the FDA's information request received with the FDA's acknowledgment of receipt of the NDA resubmission in May 2022.
If the response is considered complete by the FDA, the review clock for the NDA resubmission will then start as of the date of submission of a complete response.
For More Such Health News, visit rttnews.com
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
UK Stocks Rise On GDP Growth, Oil Price Decline
French Stocks Rise On Oil Price Drop, Middle East Concerns Persist
Indian Shares End Off Day's Lows As Oil Prices Ease
German Stocks Move Modestly Higher As Oil Prices Fall Sharply
Gold Edges Higher As Oil Prices Ease After Recent Surge
Oil Prices Edge Lower As IEA Further Cuts Oil Demand Forecast
